SGCG
Gamma-sarcoglycan
Protein Summary
Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix. This gene encodes gamma-sarcoglycan, one of several sarcolemmal transmembrane glycoproteins that interact with dystrophin. The dystrophin-glycoprotein complex (DGC) spans the sarcolemma and is comprised of dystrophin, syntrophin, alpha- and beta-dystroglycans and sarcoglycans. The DGC provides a structural link between the subsarcolemmal cytoskeleton and the extracellular matrix of muscle cells. Defects in the encoded protein can lead to early onset autosomal recessive muscular dystrophy, in particular limb-girdle muscular dystrophy, type 2C (LGMD2C). [provided by RefSeq, Oct 2008]
- ENST00000218867
- ENSP00000218867
- ENSG00000102683
- A4
- MAM
- DMDA
- SCG3
- 35DAG
- DAGA4
- DMDA1
- LGMD2C
- LGMDR5
- SCARMD2
- gamma-SG
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
protein complex | 0.91 | ||
gene perturbation | 0.9 | ||
trait | 0.86 | ||
tissue sample | 0.62 | ||
small molecule perturbation | 0.61 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 225.73 (req: < 5)
Gene RIFs: 20 (req: <= 3)
Antibodies: 127 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 225.73 (req: >= 5)
Gene RIFs: 20 (req: > 3)
Antibodies: 127 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 2
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0